Peptides and methods against diabetes

Details Peptides and methods against diabetes Peptides and methods against diabetes

1994-02-14

2000-09-05

Cunningham, Thomas M.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

530300, 530350, 530395, A61K 3800

Patent

active

061139033

ABSTRACT:
This invention relates to methods of preventing or reducing the severity of diabetes. In one embodiment, the method involves administering to the individual a peptide having substantially the sequence of a on-conserved region sequence of a T cell receptor present on the surface of T cells mediating diabetes or a fragment thereof, wherein the peptide or fragment is capable of causing an effect on the immune system to regulate the T cells. In particular, the T cell receptor has the V.beta. regional V.beta.6 or V.beta.14. In another embodiment, the method involves gene therapy. The invention also relates to methods of diagnosing diabetes by determining the presence of diabetes predominant T cell receptors.

REFERENCES:
patent: 4066510 (1978-01-01), Thilly
patent: 4544632 (1985-10-01), Yamamura et al.
patent: 4647535 (1987-03-01), Ritts, Jr.
patent: 4886743 (1989-12-01), Hood et al.
patent: 5112735 (1992-05-01), Albertini
patent: 5436319 (1995-07-01), Kung
patent: 5552300 (1996-09-01), Makrides et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5614192 (1997-03-01), Vanderbark
patent: 5643868 (1997-07-01), Weiner
Ames and Gold, "Chemical Carcinogenesis: Too Many Rodent Carcinogens," Proc. Natl. Acad. Sci. 87:7772-7776 (1990).
Allegretta et al., "T cells responsive to myelin basis protein in patients with multiplesclerosis," Science 247:718-721 (1990).
Ben-Nun et al., "Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein," Nature 292:60-61 (1981).
Bottazzo et al., "In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis," N. Engl. J. Med. 313(6) :353-360 (1985).
Clark et al., Ann. Neurol. 31:587-592 (1992).
Concannon et al., PNAS 83:6598 (1986).
Edouard et al., Eur. J. Immunol. 23:727-733 (1993).
Ertl et al., Viral Immunol. 9(1) :1-9 (1996).
Esch et al., "Observations, legends, and conjectures concerning restricted T-cell receptor usage and autoimmune disease" Crit. Rev. Immunol. 11:349 (1992).
Friedman et al., J. Exp. Med. 174:891-900 (1991).
Giegrich et al., Eur. J. Immunol. 22:753-758 (1992).
Gmelig-Meyling et al., "Assessment of In Vivo Frequency of Mutated Cells in patients with systemic lupus erythematosus," J. Exp. Med. 175:297-300 (1992).
Graur et al., Science 249:91-94 (1993).
Gregorian et al., FASEB J. 6:A1685 (1992).
Grunewald et al., Scand. J. Immunol. 34:161-168 (1992).
Grunewald et al., Eur. J. Immunol. 22:129-135 (1992).
Hafler, Immunol. Today 17:152 (1996).
Hanninen et al., J. Clin. Invest. 90:1961 (1992).
Howell et al., Proc. Natl. Acad. Sci. USA 88:10921-10925 (1991).
Infante et al., J. Immunol. 148:3385-3390 (1992).
Kappler et al., "A T-cell receptor V-beta segment that imparts reactivity to a class II major histocompatibility complex product." Cell 49:263-271 (1987).
Karin et al., J. Exp. Med. 180:2227 (1994).
Kawano et al., Cancer Eye Res. 10:789-795 (1991).
Lahesma et al., J. Immunol. 150:4125-4135 (1993).
Lee et al., Ann Neurol. 29:33-40 (1991).
Malhorta et al., "Variability in T cell receptor v.beta. gene usage in human peripheral blood lymphocytes." J. Immunology 149:1802-1808 (1992).
Martin et al., J. Immunol. 148:1359 (1992).
McKeever et al., J. Exp. Med. 184:1755 (1996).
Newsom-Davis, J. Auto Immunity 2:101 (1989).
Nicklas et al., "Use of T-cell receptor gene probes to quantify the in vivo hprt mutations in human T-lymphocytes." Mutation Res. 173:67-72.
Nicklas et al., "Molecular Analyses of In Vivo Hypoxanthine-Guanine Phosphoribosyltrasferase Mutations in Human T-Lymphocytes: II. Demonstration of a Clonal Amplification of hprt Mutant T-Lymphocytes In Vivo." Env. And Mol. Mut. 12:271-284 (1988).
Nishimoto et al., "Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice," Nature 328:432-434 (1987).
Paliard et al., Science 253:325-329 (1991).
Patten et al., "Structure, expression and divergence of T-cell receptor .beta.-chain variable regions." Nature 312:40-46 (1984).
Posnett et al., J. Clin. Invest. 85:1770-1776 (1990).
Prigione et al., Fund. Clin. Immunol. 2:161 (1994).
Vandenbark et al., "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis." Nature 341:541-544 (1989).
Shoenfeld et al., "Immunological and genetic factors in autoimmune diseases." N. Engl. J. Med. 311(16) :1019-1029 (1984).
Sellins et al., J. Immunol. 149:2323-2327 (1992).
Smith et al., Blood 81:1521-1526 (1993).
Tanuma et al., J. Exp. Med. 168:85-90 (1996).
Urban et al., "Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy." Cell 54:577-592 (1988).
Welch et al., J. Immunol. 125:186 (1993).
Yang et al., "Molecular Evidence For New Mutation at the hprt Locus in Lesch-Nyhan Patients," Nature 310:412-414 (1984).
Abe et al., Proc. Natl. Acad. Sci. U.S.A. 89:4066-4070 (1992).
Albertini et al., "T-Cell cloning to detect the mutant 6-thioquanine-resistant lymphocytes present in human peripheral blood," PNAS, USA 79:6617-6621 (1982).
Albertini et al.., "Alterations of the hprt gene in human in-vivo-derived 6-thioguanine-resistant T lymphocytes," Nature 316:369-371 (1985).
Ames and Gold, "Too Many Rodent Carcinogens: Mitogenesis Increases Mutagenesis," Science 249:970-971 (1990).
Albertini et al., "T-Cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood." PNAS, USA 79:6617-6621 (1982).
Yanagi et al., "A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains." Nature 308:145-149 (1984).
Albertini et al., "Alterations of the hprt gene in human in-vivo-derived 6-thioguanine-resistant T lymphocytes." Nature 316:369-371 (1985).
Nicklas, et al., "Use of T-cell receptor gene probes to quantify the in vivo Hprt mutations in human T-lymphocytes." Mutation Res. 173:67-72.
Gmelig-Meyling et al., "Assessment of In Vivo Frequency of Mutated T Cells in Patients with Systemic Lupus Erythematosus." J. Exp. Med. 175:297-300 (1992).
Ames and Gold, "Too Many Rodent Carcinogens: Mitogenesis Increases Mutagenesis." Science 249:970-971 (1990).
Ames and Gold, "Chemical Carcinogenesis: Too Many Rodent Carcinogens." Proc. Natl. Acad. Sci. 87:7772-7776 (1990).
Hafler, D. A. et al., Immunology Today 17(4):152-159 (Apr., 1996), "TCR usage in human and experimental demyelinating disease", Apr. 1996.
Ben-Nun, A. et al., Nature 292:60-61 (1981), "Vaccination against autoimmune encephalomyelitits with T-lymphocyte line cells reactive against myelin basic protein".
.Bottazzo, G. F., et al., N. Engl. J. med. 313(6):353-360 (1985), "In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis".
Esch, T., et al., Critical Reviews in Immunology 11(5):249-264 (1992), "Observations, legends, and conjectures concerning restricted T-cell receptor usage and autoimmune disease".
Kappler, J. W., et al., Cell 49:263-271 (1987), "A T-cell receptor V-beta segment that imparts reactivity to a class II major histocompatibility complex product".
Nishimoto, H., et al., Nature 328:432-434 (Jul. 30, 1987), "Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice".
Shoenfeld, Y., et al., N. Engl. J. Med, vol. 311 (16): 1019-1029 (Oct., 1984), "Immunological and genetic factors in autoimmune diseases".
Urban, J. L., et al., Cell 54: 577-592 (1988), "Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy".
Vandenbark, A. A., et al., Nature 341:541-544 (Oct. 12, 1989), "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis".

Affiliated with

Also associated with

Rating

Peptides and methods against diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and methods against diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and methods against diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2209205